Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

29.77 +1.71 (+6.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Assessing Travere Therapeutics: Insights From 8 Financial Analysts
 
Via Benzinga
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage. 
Via Investor's Business Daily
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts
 
Via Benzinga
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
Analyst Expectations For Travere Therapeutics's Future
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
A Preview Of Travere Therapeutics's Earnings
 
Via Benzinga
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
 
Via Benzinga
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
 
Via Benzinga
Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug
The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter. 
Via Stocktwits
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug
The company is nearing a highly anticipated approval for a kidney disease drug. 
Via Investor's Business Daily
Lattice Semiconductor, SelectQuote, Radiant Logistics And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
 
Via Benzinga
Where Travere Therapeutics Stands With Analysts
 
Via Benzinga
Analyst Ratings For Travere Therapeutics
 
Via Benzinga
3 Under-the-Radar Healthcare Companies
While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains. 
Via MarketBeat
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
The company could soon ask for approval of its only drug, Filspari, in a second disease. 
Via Investor's Business Daily
Expert Ratings For Travere Therapeutics
 
Via Benzinga
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
 
Via Benzinga
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
The company previously had an accelerated approval for its IgA nephropathy treatment. 
Via Investor's Business Daily
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
Triastek will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus... 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.